Here, we aimed to compare three SGLT2 inhibitors (dapagliflozin, empagliflozin (EMPA), and canagliflozin) and their effect on DKD in the well-characterized diabetic retinopathy mouse model, namely the Akimba mouse [15,16]. This evidence concerns the gene SLC5A2 and diabetic retinopathy.